PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas

Mostrar otras versiones (1)

OBJECTIVES: We evaluated the role of PIK3CA-mutations as mechanism of resistance to trastuzumab in primary HER2/neu-amplified uterine-serous-carcinoma (USC) cell lines. METHODS: Fifteen whole-exome-sequenced USC cell lines were tested for HER2/neu-amplification and PIK3CA-mutations. Four HER2/neu-am...

Descripción completa

Detalles Bibliográficos
Autores principales: Black, Jonathan D, Lopez, Salvatore, Cocco, Emiliano, Bellone, Stefania, Altwerger, Gary, Schwab, Carlton L, English, Diana P, Bonazzoli, Elena, Predolini, Federica, Ferrari, Francesca, Ratner, Elena, Silasi, Dan-Arin, Azodi, Masoud, Schwartz, Peter E, Santin, Alessandro D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651122/
https://www.ncbi.nlm.nih.gov/pubmed/26325104
http://dx.doi.org/10.1038/bjc.2015.306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4651122/
https://www.ncbi.nlm.nih.gov/pubmed/26325104
http://dx.doi.org/10.1038/bjc.2015.306

Ejemplares similares